News | 22 February 2023
Genomics, big data among key themes driving M&A activity in medical devices, says GlobalData
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
There is a fast resurgence in the transplant activities post COVID
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The partnership is announced at Aero India 2023, Bangalore
.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Subscribe To Our Newsletter & Stay Updated
_195_291.jpg)
